首页> 外文期刊>Radiation oncology >Light and shadows of a new technique: is?photon total-skin irradiation using helical IMRT feasible, less complex and as toxic as the electrons one?
【24h】

Light and shadows of a new technique: is?photon total-skin irradiation using helical IMRT feasible, less complex and as toxic as the electrons one?

机译:一种新技术的光与影:使用螺旋IMRT进行光子全皮照射是否可行,更简单,是否像电子一样有毒?

获取原文
获取外文期刊封面目录资料

摘要

Radiotherapy is one of the standard treatments for cutaneous lymphoma and Total Skin Electrons Beam Irradiation (TSEBI) is generally used to treat diffuse cutaneous lymphoma and some cases of localized disease. Helical IMRT (HI) allows to treat complex target with optimal dose distribution and organ at risk sparing, so helical tomotherapy has been proposed as alternative technique to TSEBI but only one preliminary report has been published. Three patients treated (from May 2013 to December 2014) with Helical IMRT, with a total dose between 24 and 30?Gy, were retrospectively evaluated. Data about dosimetric features, response and acute toxicity were registered and analyzed. Planned target coverage was compared with daily in vivo measures and dose calculation based on volumetric images used for set up evaluation as well. The patients had a mean measured surface fraction dose ranging from 1.54?Gy up to 2.0?Gy. A planned target dose ranging from 85 to 120% of prescription doses was obtained. All doses to Organs At Risk were within the required constraints. Particular attention was posed on “whole bone marrow” planned V10Gy, V12Gy and V20Gy values, ranging respectively between 23 and 43%, 20.1 and 38% and 9.8 and 24%. A comparison with the theoretical homologous values obtained with TSEBI has shown much lower values with TSEBI. Even if treatment was given in sequence to the skin of the upper and lower hemi-body, all the patients had anaemia, requiring blood transfusions, leukopenia and thrombocytopenia. Based on our limited results TSEBI should still be considered the standard method to treat total skin because of its pattern of acute and late toxicities and the dose distribution. In this particular case the better target coverage obtained with HI can be paid in terms of worse toxicity. Helical IMRT can instead be considered optimal in treating large, convex, cutaneous areas where it is difficult to use multiple electrons fields in relation with the clinical results and the limited and reversible toxicities.
机译:放射疗法是皮肤淋巴瘤的标准治疗方法之一,皮肤全电子束照射(TSEBI)通常用于治疗弥漫性皮肤淋巴瘤和某些局部疾病。螺旋IMRT(HI)可以以最佳的剂量分布和风险低的器官来治疗复杂的靶标,因此螺旋体层层析疗法已被提议作为TSEBI的替代技术,但仅发表了一份初步报告。回顾性评估了三例(2013年5月至2014年12月)接受螺旋IMRT治疗的患者,总剂量在24至30?Gy之间。记录并分析了有关剂量学特征,反应和急性毒性的数据。计划的目标覆盖率也与每日体内测量值和基于用于建立评估的体积图像的剂量计算进行了比较。患者的平均测量表面分数剂量范围为1.54?Gy至2.0?Gy。获得计划剂量的处方剂量的85%至120%。风险器官的所有剂量均在要求的限制范围内。特别关注“整个骨髓”计划的V10Gy,V12Gy和V20Gy值,分别在23%至43%,20.1%至38%和9.8%至24%之间。与TSEBI获得的理论同源值的比较显示,TSEBI具有较低的值。即使对上半身和下半身的皮肤依次进行治疗,所有患者都患有贫血,需要输血,白细胞减少症和血小板减少症。基于我们有限的结果,TSEBI由于其急性和晚期毒性的模式以及剂量分布,仍应被视为治疗全皮的标准方法。在这种特殊情况下,就毒性而言,可以用HI获得更好的目标覆盖率。螺旋IMRT可以被认为是治疗较大的,凸形的皮肤区域的最佳选择,因为这些区域难以结合临床结果以及有限且可逆的毒性使用多个电子场。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号